LIVN (LivaNova) Total Stockholders Equity : $1,243 Mil (As of Jun. 2024)

View and export this data going back to 1993. Start your Free Trial

What is LivaNova Total Stockholders Equity?

LivaNova's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $1,243 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. LivaNova's Book Value per Share for the quarter that ended in Jun. 2024 was $22.88. The ratio of a company's debt over equity can be used to measure how leveraged this company is. LivaNova's Debt-to-Equity for the quarter that ended in Jun. 2024 was 0.55.

LivaNova Total Stockholders Equity Historical Data

The historical data trend for LivaNova's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LivaNova Total Stockholders Equity Chart

LivaNova Annual Data

Trend

Apr14

Apr15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

1,383.72

1,109.27

1,294.65

1,207.62

1,277.63

LivaNova Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Stockholders Equity	Get a 7-Day Free Trial															1,240.61	1,225.47	1,277.63	1,221.54	1,242.54

LivaNova (NAS:LIVN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

LivaNova's Book Value per Share for the quarter that ended in Jun. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1242.542	-	0)	/	54.296
	=	22.88

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

LivaNova's Debt-to-Equity for the quarter that ended in Jun. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(28.585	+	648.944)	/	1242.542
	=	0.55

LivaNova Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of LivaNova's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

LivaNova Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (NAS:LIVN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

LIA:Germany LIA:Germany

Address

20 Eastbourne Terrace, London, GBR, W2 6LG

Website

https://www.livanova.com

UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Executives

Francesco Bianchi	director	C/O LIVANOVA PLC, 5 MERCHANT SQUARE, LONDON X0 W2 1AY
Daniel Jeffrey Moore	director	100 CYBERONICS BVLD, HOUSTON TX 77058
James Christopher Barry	director	7475 LUSK BLVD, SAN DIEGO CA 92121
Damien Mcdonald	officer: COO	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Michael Damon Hutchinson	officer: Chief Legal Officer	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Brooke Story	director	C/O SIGILON THERAPEUTICS, INC., 100 BINNEY STREET, SUITE 600, CAMBRIDGE MA 02142
Peter M Wilver	director
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
William A Kozy	director	C/O BECTON DICKERSON & CO, 1 BECTON DR, FRANKLIN LAKES NJ 07417
Marco Dolci	officer: SVP Global Operations, R&D	VIA BENIGNO CRESPI 17, MILAN L6 20159
Todd C Schermerhorn	director	C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Alex Shvartsburg	officer: Interim CFO	20 EASTBOURNE TERRACE, LONDON X0 W26LG
Roy Khoury	officer: President, International	5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Thad Allen Huston	officer: Chief Financial Officer	941 BLOOMFIELD ST, HOBOKEN NJ 07030
Seng Stacy Enxing	director	C/O HILL-ROM HOLDINGS, INC., SUITE 4100 180 NORTH STETSON AVENUE, CHICAGO IL 60601